Literature DB >> 9293867

CD4+ and CD8+ T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients.

B R Blazar1, P A Taylor, D A Vallera.   

Abstract

Perforin-deficient (-/-) mice were used as T-cell donors for infusion into irradiated major histocompatibility complex (MHC)-disparate recipients to investigate the requirement for perforin-mediated cytolysis during graft-versus-host disease (GVHD) generation. Administration of 5x10(6) C57BL/6 (H2b) perforin -/- splenocytes was significantly less effective in inducing GVHD lethality when given to MHC class I + II disparate B10.BR (H2k) recipients, as compared with wild-type (+/+) controls. Perforin expression by donor T cells was not required for GVHD induction because recipients given fivefold higher numbers of perforin -/- donor splenocytes uniformly succumbed to lethal GVHD. Because both CD4+ and CD8+ donor T cells are required for optimal GVHD lethality in this strain combination, to discern the relative contribution of perforin-mediated cytolysis by CD4+ and CD8+ T cells, additional studies were performed. For these latter studies, we used a sensitive assay involving the infusion of highly purified CD4+ or CD8+ T cells into sublethally irradiated MHC class II or I disparate recipients, respectively. As compared with recipients of perforin +/+ T cells, recipients of either CD4+ or CD8+ perforin -/- T-cell subsets had a significant reduction in GVHD-mediated lethality at T-cell doses that were uniformly lethal. T-cell dose titration studies established that GVHD lethality in recipients of perforin -/- CD4+ or CD8+ T cells was reduced by approximately threefold. These data are the first to indicate that approaches to limit perforin-mediated cytolysis should be similarly effective in situations in which CD4+ or CD8+ T cells dominate the GVHD response.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9293867     DOI: 10.1097/00007890-199708270-00004

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  18 in total

1.  Pathogenesis of herpes simplex virus type 1-induced corneal inflammation in perforin-deficient mice.

Authors:  E Chang; L Galle; D Maggs; D M Estes; W J Mitchell
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions.

Authors:  Ronjon Chakraverty; Hyeon-Seok Eom; Jessica Sachs; Jennifer Buchli; Pete Cotter; Richard Hsu; Guiling Zhao; Megan Sykes
Journal:  Blood       Date:  2006-06-06       Impact factor: 22.113

3.  Graft-versus-host disease impairs vaccine responses through decreased CD4+ and CD8+ T cell proliferation and increased perforin-mediated CD8+ T cell apoptosis.

Authors:  Christian M Capitini; Nicole M Nasholm; Brynn B Duncan; Martin Guimond; Terry J Fry
Journal:  J Immunol       Date:  2012-12-28       Impact factor: 5.422

4.  IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.

Authors:  T Teshima; G R Hill; L Pan; Y S Brinson; M R van den Brink; K R Cooke; J L Ferrara
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

5.  Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease.

Authors:  Jimmy A Rotolo; Branka Stancevic; Sydney X Lu; Jianjun Zhang; David Suh; Christopher G King; Lucy W Kappel; George F Murphy; Chen Liu; Zvi Fuks; Marcel R van den Brink; Richard Kolesnick
Journal:  Blood       Date:  2009-08-07       Impact factor: 22.113

Review 6.  Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.

Authors:  Arnab Ghosh; Amanda M Holland; Marcel R M van den Brink
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 7.  Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.

Authors:  Xin Feng; Kwok Min Hui; Hashem M Younes; Anthony G Brickner
Journal:  Trends Immunol       Date:  2008-10-25       Impact factor: 16.687

8.  Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model.

Authors:  Stephen C Jones; George F Murphy; Thea M Friedman; Robert Korngold
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

9.  T cell repertoire complexity is conserved after LLME treatment of donor lymphocyte infusions.

Authors:  Thea M Friedman; Joanne Filicko-O'Hara; Bijoyesh Mookerjee; John L Wagner; Delores A Grosso; Neal Flomenberg; Robert Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2007-12       Impact factor: 5.742

10.  IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation.

Authors:  Christoph Bucher; Lisa Koch; Christine Vogtenhuber; Emily Goren; Meghan Munger; Angela Panoskaltsis-Mortari; Pallavur Sivakumar; Bruce R Blazar
Journal:  Blood       Date:  2009-10-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.